Screener
BillionToOne, Inc. BLLN Prenatal — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BillionToOne, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BillionToOne, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:42 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0002070849-26-000050
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Prenatal | $94,248 | $60,852 | $190,773 | $116,929 |
| Oncology | 13,663 | 4,947 | 24,383 | 7,123 |
| Clinical trial support and other services | 1,537 | 774 | 2,680 | 1,484 |
| Total revenues | $109,448 | $66,573 | $217,836 | $125,536 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BillionToOne, Inc.'s prenatal — revenue?
- BillionToOne, Inc. (BLLN) reported prenatal — revenue of $94.25M in Q2 2026.
- How has BillionToOne, Inc.'s prenatal — revenue changed year-over-year?
- BillionToOne, Inc.'s prenatal — revenue increased by 54.9% year-over-year, from $60.85M to $94.25M.
- What does prenatal — revenue mean?
- This metric represents the total gross sales generated from the company's prenatal molecular diagnostic testing services. It reflects the market adoption and commercial performance of non-invasive screening products designed to assess fetal genetic health from maternal blood samples. This revenue stream is a primary indicator of the company's ability to scale its precision diagnostics platform within the reproductive health market.
Ask your AI about BillionToOne, Inc.'s prenatal — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude